Oncimmune Historical Income Statement

ONC Stock

14.75 0.05 0.34%

Historical analysis of Oncimmune Holdings income statement accounts such as Total Revenue of 1.4 M can show how well Oncimmune Holdings plc performed in making a profits. Evaluating Oncimmune Holdings income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Oncimmune Holdings's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Oncimmune Holdings plc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Oncimmune Holdings plc is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncimmune Holdings plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About Oncimmune Income Statement Analysis

Oncimmune Holdings plc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Oncimmune Holdings shareholders. The income statement also shows Oncimmune investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Oncimmune Holdings Income Statement Chart

At present, Oncimmune Holdings' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 1.4 M, whereas Gross Profit is forecasted to decline to about 716.4 K.

Selling General Administrative Research Development Ebitda Tax Provision

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Most accounts from Oncimmune Holdings' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Oncimmune Holdings plc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncimmune Holdings plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

	2021	2022	2023	2024 (projected)
Interest Expense	943K	2.0M	2.3M	2.4M
Depreciation And Amortization	197K	981K	1.1M	1.2M

Interest Expense Depreciation And Amortization

Oncimmune Holdings income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Tax Provision	Net Interest Income	Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		0.89	-0.43	0.19	0.18	0.23	0.02	-0.15	0.48	-0.02	0.07	0.27	-0.15	-0.4	0.68	0.09	-0.23	0.43	-0.72	0.19	0.65	-0.72
Interest Expense	0.89		-0.53	0.24	0.22	0.17	0.11	-0.08	0.24	0.04	0.09	0.18	-0.14	-0.59	0.69	0.32	-0.28	0.57	-0.87	-0.03	0.72	-0.74
Selling General Administrative	-0.43	-0.53		0.14	-0.17	0.7	-0.8	-0.62	0.35	-0.69	0.53	0.71	-0.63	0.18	-0.92	-0.74	-0.49	-0.62	0.66	0.43	0.01	0.52
Total Revenue	0.19	0.24	0.14		0.84	0.39	0.03	0.16	0.43	0.19	0.5	0.34	0.02	-0.03	0.0	-0.01	0.04	-0.03	-0.3	0.44	0.59	-0.02
Gross Profit	0.18	0.22	-0.17	0.84		-0.08	0.47	0.51	0.23	0.54	-0.04	-0.09	0.41	-0.03	0.26	0.06	0.45	-0.18	-0.42	0.41	0.28	0.0
Other Operating Expenses	0.23	0.17	0.7	0.39	-0.08		-0.88	-0.79	0.67	-0.76	0.85	0.99	-0.84	-0.17	-0.49	-0.51	-0.8	-0.08	0.09	0.36	0.63	-0.08
Operating Income	0.02	0.11	-0.8	0.03	0.47	-0.88		0.92	-0.47	0.93	-0.7	-0.88	0.92	0.1	0.67	0.6	0.86	0.17	-0.37	-0.22	-0.34	-0.16
Ebit	-0.15	-0.08	-0.62	0.16	0.51	-0.79	0.92		-0.38	0.99	-0.52	-0.82	0.98	0.43	0.54	0.57	0.93	0.09	-0.21	-0.18	-0.32	-0.02
Research Development	0.48	0.24	0.35	0.43	0.23	0.67	-0.47	-0.38		-0.31	0.42	0.7	-0.38	0.1	-0.03	-0.52	-0.27	-0.19	-0.18	0.41	0.56	-0.16
Ebitda	-0.02	0.04	-0.69	0.19	0.54	-0.76	0.93	0.99	-0.31		-0.52	-0.79	0.97	0.38	0.64	0.58	0.91	0.14	-0.31	-0.15	-0.24	-0.11
Cost Of Revenue	0.07	0.09	0.53	0.5	-0.04	0.85	-0.7	-0.52	0.42	-0.52		0.76	-0.62	-0.01	-0.42	-0.1	-0.66	0.23	0.11	0.17	0.65	-0.03
Total Operating Expenses	0.27	0.18	0.71	0.34	-0.09	0.99	-0.88	-0.82	0.7	-0.79	0.76		-0.86	-0.21	-0.48	-0.59	-0.8	-0.16	0.08	0.4	0.59	-0.09
Income Before Tax	-0.15	-0.14	-0.63	0.02	0.41	-0.84	0.92	0.98	-0.38	0.97	-0.62	-0.86		0.48	0.55	0.5	0.97	0.04	-0.13	-0.16	-0.44	-0.01
Total Other Income Expense Net	-0.4	-0.59	0.18	-0.03	-0.03	-0.17	0.1	0.43	0.1	0.38	-0.01	-0.21	0.48		-0.11	-0.07	0.52	-0.29	0.51	0.09	-0.37	0.3
Net Income	0.68	0.69	-0.92	0.0	0.26	-0.49	0.67	0.54	-0.03	0.64	-0.42	-0.48	0.55	-0.11		0.59	0.42	0.56	-0.77	-0.22	0.22	-0.61
Income Tax Expense	0.09	0.32	-0.74	-0.01	0.06	-0.51	0.6	0.57	-0.52	0.58	-0.1	-0.59	0.5	-0.07	0.59		0.33	0.76	-0.45	-0.65	0.09	-0.32
Net Income From Continuing Ops	-0.23	-0.28	-0.49	0.04	0.45	-0.8	0.86	0.93	-0.27	0.91	-0.66	-0.8	0.97	0.52	0.42	0.33		-0.15	-0.03	-0.09	-0.53	0.09
Tax Provision	0.43	0.57	-0.62	-0.03	-0.18	-0.08	0.17	0.09	-0.19	0.14	0.23	-0.16	0.04	-0.29	0.56	0.76	-0.15		-0.52	-0.54	0.44	-0.54
Net Interest Income	-0.72	-0.87	0.66	-0.3	-0.42	0.09	-0.37	-0.21	-0.18	-0.31	0.11	0.08	-0.13	0.51	-0.77	-0.45	-0.03	-0.52		0.26	-0.6	0.56
Interest Income	0.19	-0.03	0.43	0.44	0.41	0.36	-0.22	-0.18	0.41	-0.15	0.17	0.4	-0.16	0.09	-0.22	-0.65	-0.09	-0.54	0.26		0.14	0.16
Reconciled Depreciation	0.65	0.72	0.01	0.59	0.28	0.63	-0.34	-0.32	0.56	-0.24	0.65	0.59	-0.44	-0.37	0.22	0.09	-0.53	0.44	-0.6	0.14		-0.32
Selling And Marketing Expenses	-0.72	-0.74	0.52	-0.02	0.0	-0.08	-0.16	-0.02	-0.16	-0.11	-0.03	-0.09	-0.01	0.3	-0.61	-0.32	0.09	-0.54	0.56	0.16	-0.32

Click cells to compare fundamentals

Oncimmune Holdings Account Relationship Matchups

Oncimmune Holdings income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	500K	740K	197K	981K	1.1M	1.2M
Interest Expense	626K	954K	943K	2.0M	2.3M	2.4M
Selling General Administrative	8.2M	5.7M	7.1M	434K	499.1K	474.1K
Total Revenue	509K	3.7M	3.9M	1.2M	1.3M	1.4M
Gross Profit	(28K)	2.9M	1.5M	792K	910.8K	716.4K
Other Operating Expenses	10.4M	8.9M	12.4M	5.4M	6.2M	7.5M
Operating Income	(9.3M)	(5.1M)	(8.6M)	(4.2M)	(3.8M)	(4.0M)
Ebit	(9.5M)	(5.2M)	(7.4M)	(5.4M)	(4.9M)	(5.1M)
Research Development	1.7M	1.6M	1.5M	1.3M	1.4M	1.3M
Ebitda	(9.0M)	(4.5M)	(7.2M)	(4.4M)	(4.0M)	(4.2M)
Cost Of Revenue	537K	865K	2.4M	360K	414K	707.1K
Total Operating Expenses	9.8M	8.0M	10.0M	5.0M	5.8M	6.8M
Income Before Tax	(9.8M)	(5.7M)	(9.5M)	(5.9M)	(5.3M)	(5.6M)
Total Other Income Expense Net	(515K)	(551K)	(943K)	(1.7M)	(1.5M)	(1.4M)
Net Income	(8.5M)	(4.6M)	(9.5M)	4.1M	3.7M	3.9M
Income Tax Expense	(1.3M)	(1.1M)	(17K)	223K	200.7K	210.7K
Net Income From Continuing Ops	(8.5M)	(4.6M)	(9.5M)	(6.2M)	(5.5M)	(5.8M)
Net Income Applicable To Common Shares	(8.0M)	(8.5M)	(4.6M)	(9.5M)	(8.6M)	(9.0M)
Tax Provision	(1.3M)	(1.1M)	(17K)	223K	256.5K	269.3K
Net Interest Income	(515K)	(551K)	(943K)	(1.8M)	(1.6M)	(1.5M)
Reconciled Depreciation	500K	740K	1.4M	981K	1.1M	653.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Other Information on Investing in Oncimmune Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oncimmune Historical Income Statement

About Oncimmune Income Statement Analysis

Oncimmune Holdings Income Statement Chart

Tax Provision

Oncimmune Holdings income statement Correlations

Oncimmune Holdings Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oncimmune Holdings income statement Accounts

Also Currently Popular

Other Information on Investing in Oncimmune Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 0.99	Other Operating Expenses
Ebitda	+ 0.99	Ebit
Income Before Tax	+ 0.98	Ebit
Income Before Tax	+ 0.97	Ebitda
Net Income From Continuing Ops	+ 0.97	Income Before Tax
Ebitda	+ 0.93	Operating Income

Net Income	- 0.92	Selling General Administrative
Total Operating Expenses	- 0.88	Operating Income
Operating Income	- 0.88	Other Operating Expenses
Net Interest Income	- 0.87	Interest Expense
Income Before Tax	- 0.86	Total Operating Expenses
Income Before Tax	- 0.84	Other Operating Expenses